Question · asked by 1 review
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo: Incidence of serious adverse events
- Population
- adults with alopecia areata
- Intervention
- Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib)
- Comparison
- placebo
- Outcome
- Incidence of serious adverse events
It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Incidence of serious adverse events · adults with alopecia areata It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty). Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane Headline outcomes only | RR 0.33 [0.01, 7.94] | 1 study · 78 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.